Wedbush analyst Robert Driscoll initiated coverage of Avalo Therapeutics (AVTX) with an Outperform rating and $18 price target Discover the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback